Although CTCs that expressed prostate-cancer-related genes were eliminated by the given therapy, PSMA+ CTCs identified patients at high risk of relapse, while AR-FL-pos CTCs, together with AR-V7-pos CTCs, were associated with therapeutic failure [20]. This evidence concerns the gene FOLH1 and prostate cancer.